Paper Details

  1. Home
  2. Paper Details

Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.

Author: , ClinchThomas, HauserRobert A, IsaacsonStuart

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A randomized, double-blind, placebo-controlled study of 182 patients with Parkinson's disease (PD) found that trimethobenzamide helped reduce nausea and vomiting during the first 8 weeks of apomorphine therapy, but was not needed thereafter. Trimethobenzamide did not worsen parkinsonism or affect the 'on' response after apomorphine injection.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Nausea and vomiting can occur in Parkinson's disease (PD) patients initiated on apomorphine subcutaneous injections and antiemetic prophylaxis is recommended per product labeling. Data suggest long-term antiemetic prophylaxis may not be needed, although this has not been systematically s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.parkreldis.2014.08.010

データ提供：米国国立医学図書館（NLM）

Trimethobenzamide: A Helpful Hand in Navigating Apomorphine Therapy

This randomized, placebo-controlled trial explores the efficacy of trimethobenzamide in controlling nausea and vomiting associated with apomorphine therapy in Parkinson's disease (PD) patients. The study evaluates the effectiveness of trimethobenzamide as an antiemetic prophylactic, examining its impact on nausea and vomiting severity, motor function, and overall patient well-being. This research provides valuable insights into the management of nausea and vomiting in PD patients receiving apomorphine therapy, offering guidance on the appropriate use of trimethobenzamide.

Trimethobenzamide: A Life Raft in the Sea of Nausea and Vomiting

This research reveals that trimethobenzamide can effectively reduce nausea and vomiting during the initial stages of apomorphine therapy in Parkinson's disease (PD) patients. The findings suggest that while long-term prophylaxis may not be necessary, trimethobenzamide can provide a helpful hand in navigating the initial phase of apomorphine treatment, improving patient comfort and overall well-being. This study underscores the importance of personalized medication management in PD, tailoring treatment strategies to individual patient needs and optimizing therapeutic outcomes.

Trimethobenzamide: A Guiding Star in the Desert of Apomorphine Therapy

Navigating the desert of apomorphine therapy can be challenging, particularly due to the potential for nausea and vomiting. This study sheds light on the effectiveness of trimethobenzamide as an antiemetic prophylactic, demonstrating its ability to mitigate these distressing side effects. The findings suggest that trimethobenzamide can provide a guiding star for patients undergoing apomorphine therapy, ensuring a smoother transition and improving overall patient well-being.

Dr.Camel's Conclusion

This randomized, placebo-controlled trial reveals that trimethobenzamide can effectively reduce nausea and vomiting associated with apomorphine therapy in Parkinson's disease (PD) patients. The findings suggest that while long-term prophylaxis may not be necessary, trimethobenzamide can provide a helpful hand in navigating the initial phase of apomorphine treatment, improving patient comfort and overall well-being. This study underscores the importance of personalized medication management in PD, tailoring treatment strategies to individual patient needs and optimizing therapeutic outcomes.
Date :
  1. Date Completed 2015-07-20
  2. Date Revised 2014-12-02
Further Info :

Pubmed ID

25239603

DOI: Digital Object Identifier

10.1016/j.parkreldis.2014.08.010

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.